share_log

HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $36

Benzinga Real-time News ·  Mar 11, 2021 19:32

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $33 to $36.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment